Leigh Hsu is a biotechnology executive with 25 years of experience in the biopharma industry. Dr. Hsu most recently served as SVP of Business Development with CARsgen for seven years, and prior to that, he was with Lpath for six years as VP of Corporate Development & Strategy. He earned his Ph.D. in molecular pathology from UC: San Diego and an MBA from UC: Irvine.

Charles Hinkle began his career at Bain & Co. and Bain Capital and then joined an automotive foundry as CEO, where he led this manufacturer’s growth from $4M to $50M before selling to a PE firm. He graduated summa cum laude from W&L, earned his CPA certification, and graduated as a Baker Scholar from HBS.

CEO of Zylö; former CEO of Lpath; served on 17 boards (4 public); board member for San Diego Venture Group (Chairman for 2 years). BA summa cum laude from UVA; HBS

SVP/CMO for Eyepoint Pharmaceuticals (~8yrs); SVP/CDO for Lpath (3.5 yrs); VP & Therapeutic Unit Head for Alcon; Exec. Director, Specialty Care for Pfizer; University of Rome medical degree

Co-inventor of the Z-pod technology while a post-doc at Albert Einstein College of Medicine; VP of R&D at Zylo Therapeutics